Continuous Glucose Monitoring Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

The Global Continuous Glucose Monitoring Market was estimated at USD 10.9 billion in 2024 and is estimated to grow from USD 12.4 billion in 2025 to USD 47.1 billion by 2034, at a CAGR of 16%, according to the latest report published by Global Market Insights Inc.

The global surge in Type 1 and Type 2 diabetes cases is significantly boosting demand for CGM systems, as they provide real-time glucose tracking and help manage the disease more effectively than traditional fingerstick methods.

Rising Adoption of Sensors

The sensors segment held a notable share in 2024. These components are critical for capturing real-time glucose readings in the interstitial fluid and transmitting accurate data to monitoring devices or mobile apps. As users demand longer wear times, greater comfort, and fewer calibrations, manufacturers are investing heavily in sensor innovation. The segment growth is also driven by technological improvements like extended sensor life, flexible wearables, and factory calibration. This growth reflects a strong shift toward convenience, especially for users managing diabetes outside of traditional clinical settings.

Homecare Settings to Gain Traction

The home care settings segment will grow at a decent CAGR during 2025-2034. With patients increasingly prioritizing independence and remote care options, CGM systems are becoming essential tools for daily glucose monitoring at home. These devices allow users to manage their condition in real time, while sharing data with caregivers or physicians through digital platforms. This shift toward home-based diabetes management is not only reducing hospital visits but also empowering patients to take proactive control of their health.

Regional Insights

North America to Emerge as a Lucrative Region

North America continuous glucose monitoring market held a sustainable share in 2024, supported by a high diabetes prevalence, strong healthcare infrastructure, and favorable reimbursement policies. Major players are heavily investing in expanding access to CGM systems across both Type 1 and Type 2 diabetes patients, including those on non-insulin therapies. With regulatory agencies like the FDA streamlining approvals and the expansion of remote monitoring programs, North America continues to set the pace for innovation and adoption in this space.

Major players in the continuous glucose monitoring market are Senseonics, Medtrum Technologies, i-SENS, F. Hoffmann-La Roche, Med Trust, Abbott Laboratories, Zhejiang POCTech, Sinocare, A. Menarini Diagnostics, Dexcom, and Medtronic.

To solidify their position in the competitive CGM landscape, companies are focusing on technological advancement, strategic partnerships, and regulatory navigation. Leading firms are improving sensor accuracy, extending wear duration, and enabling seamless integration with insulin delivery systems and digital health apps. Collaborations with healthcare providers, insurers, and digital health startups are helping companies broaden access and enhance user engagement. Additionally, firms are investing in direct-to-consumer marketing and patient education to drive brand loyalty. Regulatory strategy also plays a crucial role, with companies working closely with agencies to secure approvals for over-the-counter use and expanded indications—ultimately positioning their products as standard tools for comprehensive diabetes care.    Show more